Clinical Trial Update: A Phase I Study of Infusional Paclitaxel With the P-Glycoprotein Antagonist PSC 833 [Phase 1]

View source ↗

Summary

Phase I study of infusional paclitaxel combined with the P-glycoprotein antagonist PSC 833 (valspodar) in patients with various cancers; the trial has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Lymphoma
• Ovarian Cancer
• Renal Cell Carcinoma

Drugs mentioned

• PSC 833 (valspodar)
• Taxol (paclitaxel)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Breast Cancer, Cancer | Phase 1 | Status: COMPLETED